Cross-sectional study of bone density in asthmatic children.

R. J. Hopp, J. A. Degan, J. Phelan, J. Lappe, G. C. Gallagher

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

The emphasis in treatment of asthma in children has shifted from bronchodilators to inhaled anti-inflammatory medications, including inhaled corticosteroids (ICS). Children with chronic asthma and moderate to severe symptoms have been targeted as particularly deserving of maintenance therapy with ICS. We have previously reported a cross-sectional study of bone density in children treated with ICS. There was no significant difference between the total bone density of asthmatic patients and controls. We sought to extend the information available on bone density in asthmatic children by evaluating 15 asthmatic subjects taking daily ICS (beclomethasone dipropionate) and comparing them with age- and sex-matched controls. We compared total and regional bone density, bone age, and calcium intakes in these subjects. Asthmatic subjects were on ICS for 4-60 months, with doses ranging from 200 to 450 micrograms/day. There was no significant difference between asthmatics and matched controls for height, weight, % RDA Ca2+, or bone age. The asthmatic subjects had bone density (total and regional measurements) equivalent to their controls. These results provide additional support for the safety of low-dose ICS on bone density in asthmatic children.

Original languageEnglish
Pages (from-to)189-192
Number of pages4
JournalPediatric Pulmonology
Volume20
Issue number3
StatePublished - Sep 1995

Fingerprint

Bone Density
Adrenal Cortex Hormones
Cross-Sectional Studies
Asthma
Beclomethasone
Bone and Bones
Bronchodilator Agents
Anti-Inflammatory Agents
Calcium
Safety
Weights and Measures
Therapeutics

All Science Journal Classification (ASJC) codes

  • Pediatrics, Perinatology, and Child Health
  • Pulmonary and Respiratory Medicine

Cite this

Hopp, R. J., Degan, J. A., Phelan, J., Lappe, J., & Gallagher, G. C. (1995). Cross-sectional study of bone density in asthmatic children. Pediatric Pulmonology, 20(3), 189-192.

Cross-sectional study of bone density in asthmatic children. / Hopp, R. J.; Degan, J. A.; Phelan, J.; Lappe, J.; Gallagher, G. C.

In: Pediatric Pulmonology, Vol. 20, No. 3, 09.1995, p. 189-192.

Research output: Contribution to journalArticle

Hopp, RJ, Degan, JA, Phelan, J, Lappe, J & Gallagher, GC 1995, 'Cross-sectional study of bone density in asthmatic children.', Pediatric Pulmonology, vol. 20, no. 3, pp. 189-192.
Hopp RJ, Degan JA, Phelan J, Lappe J, Gallagher GC. Cross-sectional study of bone density in asthmatic children. Pediatric Pulmonology. 1995 Sep;20(3):189-192.
Hopp, R. J. ; Degan, J. A. ; Phelan, J. ; Lappe, J. ; Gallagher, G. C. / Cross-sectional study of bone density in asthmatic children. In: Pediatric Pulmonology. 1995 ; Vol. 20, No. 3. pp. 189-192.
@article{f492fd6374d04e1bae586f6f0b376414,
title = "Cross-sectional study of bone density in asthmatic children.",
abstract = "The emphasis in treatment of asthma in children has shifted from bronchodilators to inhaled anti-inflammatory medications, including inhaled corticosteroids (ICS). Children with chronic asthma and moderate to severe symptoms have been targeted as particularly deserving of maintenance therapy with ICS. We have previously reported a cross-sectional study of bone density in children treated with ICS. There was no significant difference between the total bone density of asthmatic patients and controls. We sought to extend the information available on bone density in asthmatic children by evaluating 15 asthmatic subjects taking daily ICS (beclomethasone dipropionate) and comparing them with age- and sex-matched controls. We compared total and regional bone density, bone age, and calcium intakes in these subjects. Asthmatic subjects were on ICS for 4-60 months, with doses ranging from 200 to 450 micrograms/day. There was no significant difference between asthmatics and matched controls for height, weight, {\%} RDA Ca2+, or bone age. The asthmatic subjects had bone density (total and regional measurements) equivalent to their controls. These results provide additional support for the safety of low-dose ICS on bone density in asthmatic children.",
author = "Hopp, {R. J.} and Degan, {J. A.} and J. Phelan and J. Lappe and Gallagher, {G. C.}",
year = "1995",
month = "9",
language = "English",
volume = "20",
pages = "189--192",
journal = "Pediatric Pulmonology",
issn = "8755-6863",
publisher = "Wiley-Liss Inc.",
number = "3",

}

TY - JOUR

T1 - Cross-sectional study of bone density in asthmatic children.

AU - Hopp, R. J.

AU - Degan, J. A.

AU - Phelan, J.

AU - Lappe, J.

AU - Gallagher, G. C.

PY - 1995/9

Y1 - 1995/9

N2 - The emphasis in treatment of asthma in children has shifted from bronchodilators to inhaled anti-inflammatory medications, including inhaled corticosteroids (ICS). Children with chronic asthma and moderate to severe symptoms have been targeted as particularly deserving of maintenance therapy with ICS. We have previously reported a cross-sectional study of bone density in children treated with ICS. There was no significant difference between the total bone density of asthmatic patients and controls. We sought to extend the information available on bone density in asthmatic children by evaluating 15 asthmatic subjects taking daily ICS (beclomethasone dipropionate) and comparing them with age- and sex-matched controls. We compared total and regional bone density, bone age, and calcium intakes in these subjects. Asthmatic subjects were on ICS for 4-60 months, with doses ranging from 200 to 450 micrograms/day. There was no significant difference between asthmatics and matched controls for height, weight, % RDA Ca2+, or bone age. The asthmatic subjects had bone density (total and regional measurements) equivalent to their controls. These results provide additional support for the safety of low-dose ICS on bone density in asthmatic children.

AB - The emphasis in treatment of asthma in children has shifted from bronchodilators to inhaled anti-inflammatory medications, including inhaled corticosteroids (ICS). Children with chronic asthma and moderate to severe symptoms have been targeted as particularly deserving of maintenance therapy with ICS. We have previously reported a cross-sectional study of bone density in children treated with ICS. There was no significant difference between the total bone density of asthmatic patients and controls. We sought to extend the information available on bone density in asthmatic children by evaluating 15 asthmatic subjects taking daily ICS (beclomethasone dipropionate) and comparing them with age- and sex-matched controls. We compared total and regional bone density, bone age, and calcium intakes in these subjects. Asthmatic subjects were on ICS for 4-60 months, with doses ranging from 200 to 450 micrograms/day. There was no significant difference between asthmatics and matched controls for height, weight, % RDA Ca2+, or bone age. The asthmatic subjects had bone density (total and regional measurements) equivalent to their controls. These results provide additional support for the safety of low-dose ICS on bone density in asthmatic children.

UR - http://www.scopus.com/inward/record.url?scp=0029364019&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029364019&partnerID=8YFLogxK

M3 - Article

VL - 20

SP - 189

EP - 192

JO - Pediatric Pulmonology

JF - Pediatric Pulmonology

SN - 8755-6863

IS - 3

ER -